Ceritinib is a novel, selective ALK inhibitor which has been shown to induce complete tumor regression of crizotinib-resistant xenograft models of ALK1 ALCL. 6 A phase 1 dose-escalation study of ceritinib (ASCEND-1; this trial was registered at www.clinicaltrials.gov as #NCT01283516) was conducted in patients with advanced or metastatic ALK-positive tumors. 7 Among a total of 304 patients, 3 had relapsed with ALK1 ALCL. All patients were enrolled during the expansion phase of the study, with 1 included in the analysis reported previously. 7 Here, we report in detail on the safety and efficacy of ceritinib in these 3 patients.
In the ASCEND-1 study, all anatomical responses were assessed as per Response Evaluation Criteria in Solid Tumors 1.0 criteria, as patients with a variety of ALK1 cancers were enrolled. Responses were confirmed by computerized tomography or positron emission tomography/computerized tomography using fludeoxyglucose tracer. Full details of the trial design have been reported previously. 7 All 3 patients with ALK-positive ALCL initiated ceritinib treatment at a dose of 750 mg/d. Two patients achieved a complete response (CR) and 1 had a partial response (PR) ( Table 1 ). The patient with a PR achieved a maximal tumor reduction of 94.8% from baseline. As of January 2015, responses were ongoing for all 3 patients, with durations ranging from $20 months to $26 months (Table 1) . Two patients experienced adverse events that required ceritinib dose reductions (Table 1 ) but continue to receive ceritinib at the reduced dose level. The other patient continues to receive ceritinib at 750 mg/d. Toxicities observed in this subgroup analysis were mainly grade 1 or 2. Overall, the common adverse events observed in ALK-positive ALCL were similar to those observed with ALK-positive non-small cell lung cancer. 7 Treatment of patients with chemotherapy-relapsed advanced ALK-rearranged ALCL can be challenging and generally has a poor outcome. 2, 3 Here, we have shown that the ALK inhibitor ceritinib is active in patients with ALCL who have relapsed after anthracyclinebased chemotherapy. Although the number of patients with ALCL treated in our study is small, it is noteworthy that all 3 patients maintained responses to ceritinib salvage therapy for at least 20 months despite having had early relapses after anthracycline chemotherapy, a characteristic known to be associated with a poorer prognosis than late relapse. 3 Crizotinib, another ALK inhibitor, has also shown activity in patients with ALK-positive ALCL who had progressed on 1 or more lines of therapy. [8] [9] [10] Interestingly, both ceritinib and crizotinib have shown durable responses of .26 months (still ongoing) and 40 months, respectively. 8 Additionally, crizotinib showed activity in patients with previous autologous bone marrow transplant, but transplant-related toxicities limited the long-term administration of crizotinib. 8 These results support our observations that treatment with ALK inhibitor-targeted therapy can be effective in patients with ALK1 ALCL.
Given the high remission rate, long duration of remission, and acceptable tolerability of treatment with ceritinib in the 3 patients with ALK1 ALCL in the ASCEND-1 study, ceritinib may have a role in the treatment of patients with ALK-positive ALCL. Two prospective studies (#NCT02343679 and #CLDK378A2407) are currently planned/ enrolling to further evaluate the activity of ceritinib in patients with hematologic malignancies, including ALCL. 
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